FEATURES OF DEVELOPMENT AND PROGRESSION OF COMORBID LESIONS IN THE HEPATOBILIARY SYSTEM AND THE PANCREAS IN PATIENTS WITH OSTEOARTHROSIS: AGE AND GENDER ASPECTS

L.O. Voloshyna

Higher State Educational Establishment of Ukraine "Bukovinian State Medical University", Chernivtsi

Abstract. Objective - to study the age and gender characteristics of the development and progression of comorbid lesions in the hepatobiliary system and pancreas in patients with osteoarthritis (OA) and their effects on the manifestations and results of treatment of the underlying illness. Materials and methods. 312 patients with OA of I-III radiological stages on Kellgren-Lawrence grading scale were involved in dynamic observations during three years. Methods: clinical, laboratory-biochemical and instrumental ones. Results. In patients with OA in the initial stages (under the age of 50), there are though frequent but mild forms of cholecystopathies, which have no effect on the implementation and effectiveness of modern antireumatic drugs. In patients with OA aged over 50, especially 60, lesions of the hepatobiliary system and the pancreas against the background of different stages of obesity progressively increase quantitatively and become increasingly marked which is accompanied by secondary enterocolopathies with disorders in motility, digestive processes, absorption and significant progressive biochemical disorders, including mineral metabolism. With the age progression of lesions of the hepatobiliary system, pancreas and the secondary intestinal changes, the results of anti-rheumatic therapy worsen, especially those of chondroprotectors, the frequency of side effects due to their use increases. The study of chrono aspects of developing comorbid pathology in the hepatobiliary system and the pancreas in patients with osteoarthritis can serve as arguments for improving the existing schemes of antireumatic therapy, to be one of the important factors in the development of personified approaches to the treatment of such a contingent of patients.

Conclusion. It is appropriate to include modern multicomponent herbal medicines that have a systemic effect on the comorbid lesions of the hepatobiliary system, the pancreas and the intestines in therapeutic complexes for patients with osteoarthritis to optimize their treatment.

Key words: osteoarthrosis, comorbidity, hepatobiliary system lesions, pancreas, age aspects.

Ключові слова: остеоартроз, коморбідність, ураження гепатобіліарної системи, підшлункової залози, вікові аспекти.

ОСОБЛИВОСТІ РОЗВИТКУ ТА ПРОГРЕСУВАННЯ КОМОРБІДНИХ УРАЖЕНЬ ГЕПАТОБІЛІАРНОЇ СИСТЕМИ І ПІДШЛУНКОВОЇ ЗАЛОЗИ У ХВОРИХ НА ОСТЕОАРТРОЗ: ВІКОВІ І ГЕНДЕРНІ АСПЕКТИ

Л.О. Волошина

Резюме. Мета - дослідити вікові та гендерні особливості розвитку й прогресування коморбідних уражень гепатобіліарної системи і підшлункової залози у хворих на остеоартроз (OA) та їх вплив на прояві й результати лікування основної небудь. Матеріал і методи. Динамічні спостереження проводили трьох років проведено за 312 хворими на OA I-III рентгенологічної стадій за Келлгреном-Лоуренсом. Методи: клінічні, лабораторно-біохімічні, інструментальні. Результати. У хворих на OA на початкових етапах (у віці до 50 років) спостерігаються хоч і часті, але легкі форми холецистопатій, що не впливають на реалізацію і ефективність сучасних протиревматичних засобів. У пацієнтів із OA старше 50, особливо 60 років, прогресивно зростають кількісно та стають все більш вираженими ураження гепатобіліарної системи і підшлункової залози на тлі різних ступенів ожиріння, що супроводжується вторинними ентероколопатіями з порушеннями моторики, процесів травлення, всмоктування та значними прогресуючими біохімічними порушеннями, в т.ч. мінерального обміну. З віковим прогресуванням уражень гепатобіліарної системи, підшлункової залози та вторинних змін кишечнику посідаються результати протиревматичної терапії, особливо дії хондропротекторів, зростає частота побічних ефектів. Дослідження хроноспектральних формування коморбідної патології гепатобіліарної системи і підшлункової залози у хворих на остеоартроз може слугувати аргументами до вдосконалення існуючих схем протиревматичної терапії, бути одним із важливих факторів побудови персоніфікованих підходів до лікування такого контингенту пацієнтів.

Висновок. Хворим на остеоартроз в терапевтичні комплекси з метою оптимізації лікування доцільно включати сучасні полікомпонентні рослинні ліки, що володіють
Introduction

Osteoarthritis (OA) is a chronic progressive age-dependent joint disease of degenerative and inflammatory nature, characterized by cartilage lesions, bone epiphysis remodeling, by the development of osteophytes, and by a persistent deformation of joints and their function impairment with age [3]. This is the most common pathology of the musculoskeletal system, which ranks 11th among the diseases with the highest share to the global disability. Population prevalence of OA in different countries is 12-20%, but at the age of 60 it is 50% and over 80 - 100 percent [2, 7, 12]. Due to the global trend towards the population’s ageing, this problem will be becoming increasingly socially important [4, 13].

Among the recognized risk factors for OA there are local ones that are modified (joint lesion, joint position / axis, muscle strength, physical activity), system modified factors (obesity, bone metabolism, eating habits), unmodified system factors (age, sex, genetic predisposition, ethnicity) [3, 9].

Current step-by-step treatment regimens for patients with OA involve using nonpharmacological (educational component, wearing orthoses, insoles, dressings, using sticks, etc.) and pharmacological means (use of nonsteroidal anti-inflammatory drugs [NSAIDs], analgesics, corticosteroids (rarely), chondroprotectors, local pharmaceutical anti-inflammatory drugs [NSAIDs], analgesics, etc.) and pharmacological means (use of nonsteroidal anti-inflammatory drugs [NSAIDs], analgesics, corticosteroids (rarely), chondroprotectors, local pharmaco-therapy, surgery, cartilage allotransplantation [2, 8].

At the same time, it has been stated that OA is one of the diseases, which is characterized by, growing with age, high comorbidity rate [2, 7, 10]. One should keep in mind that comorbidity has been recognized as one of the major problems of modern medicine, which has been intensively studied as it makes treatment much more complicated and expensive and contributes to polypharmacy and complications caused by drug therapy [5, 6, 9]. With the age and the underlying disease advancing the comorbid processes become more numerous, more pronounced and rather various which requires constant additions to the existing standards of treatment [7, 13]. However, the studies on the pathogenetic “contribution” of comorbidity into the underlying pathogenesis of OA and, hence, justifying the additions to the treatment regimens of patients with OA are at an early stage. Even though it has been considered to be one of the important principles in developing personalized treatment approaches.

The articular pain is known to be a leading phenomenon in OA patients, that is why they are the main “consumers” of NSAIDs, they have to take their numerous courses of different duration [3, 8, 9]. However, in this situation one can often observe negative effects of NSAIDs, including cardiovascular events.
complications of the digestive system (NSAIDs-gastroenteropathies, gastrointestinal bleeding, hepatotoxic manifestations, etc.) [3, 9]. The feasibility of chondroprotectors in treatment of patients with OA has been discussed since 2012 [8]. In particular, the experts of the American College of Rheumatologists consider their use in OA inappropriate while The European League Against Rheumatism (EULAR) do not share these approaches [14]. It is believed that lowering efficacy of chondroprotectors in OA may be due to a disorder in their absorption in the affected digestive canal and to other polynutrient deficiencies that affect negatively local and systemic metabolic processes, including articular apparatus. Different versions of entero-colopathies in most cases result from chronic lesions of the hepatobiliary system, of the pancreas or those due to the influence of a number of long-used drugs. Traditionally, treatment of these diseases is the prerogative of gastroenterologists. Their possible negative impact on the manifestations of OA or its course has been overlooked both by rheumatologists and gastroenterologists (except adverse reactions). It happens frequently that the dominant comorbid processes in cardiovascular, endocrine and other systems in the OA patients are not paid proper attention and, therefore, the relationship between pathogenic lesions in the gastrointestinal tract and OA has not been studied properly.

**Objective:** to study the features of the development and progression of comorbid lesions of the hepatobiliary system and the pancreas in patients with OA in age and gender aspects.

**Materials and methods**

The study involved 312 patients with OA aged from 37 to 76 (mean age - 58,6) who were observed for three years. They were mostly women - 254 individuals (81,41%). OA was primarily diagnosed in Chernivtsi hospital rheumatological departments according to recommendations of EULAR (2010) [14] and the Order of the Ministry of Health of Ukraine № 676 of 12.10.2006 "Clinical protocol for provision of medical care to rheumatological patients" Diagnosis of comorbid diseases were verified in accordance with relevant protocols of MOH of Ukraine and confirmed by gastroenterologists. Control visits, depending on the state of the underlying or specified comorbid diseases, were called every 3-6 months. We applied endoscopic examination (upper and if necessary lower endoscopy), ultrasonographic, laboratory and biochemical (fractions of bilirubin, activity of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), γ-glutamyltransferase (GGT), rates of glucose, amylase, calcium, phosphorus, magnesium, iron, C-reactive protein (CRP), lipogram), as well as scatological examinations in biochemical laboratories of Chernivtsi regional diagnostic center. We also took into consideration the body mass index and type of obesity. The study also involved 30 practically healthy volunteers of similar age and sex in terms of biological indices of blood (control group). The materials of outpatient primary documentation have been studied as well.

All patients received basic treatment according to the order №676 of MOH of Ukraine (diet, NSAIDs chondroprotectors, proton pump inhibitor (PPI), a topical treatment) and appointed by specialists antihypertensive, anti-ischemic, hepatoprotective, cholagogue or polynzyme drugs etc.

Exclusion criteria: patients with secondary OA, patients with primary OA who had experienced myocardial infarction or stroke, those with active gastroduodenal ulcer or severe lesions of internal organs, acute infectious, oncolematological processes and endocrine hereditary forms of obesity or those suffering from viral liver disease.

This paper is a further advanced study of our earlier findings [1].

Statistical data processing was made using licensed software Microsoft Excel, 2007. We determined the arithmetic mean (M), standard deviation (Sd), standard error of the arithmetic mean (m). The reliability of rate differences between the groups was established by using Student's t-test. Differences with p <0.05 were considered to be statistically significant.

**Results**

In order to study age features in developing comorbid processes of the hepatobiliary system (GBS) and the pancreas (PS) and considering age features in the development and progression of OA, the contingent of patients was divided into three groups: those under 50 years, 51-60 years and over 60 years. Bearing in mind certain dependence and impact of gastroduodenal lesions on the development of cholecystohepatopathies and pancreatic diseases, we paid attention to these diseases as well. We considered it necessary to examine the degrees of obesity, as in this pathological condition liver and pancreatic lesions are quite common. The obtained data under this approach are summarized in table 1.

As one can see in table 1, in the group of patients aged under 50 the lesions of the digestive system are clinically moderate, they manifest themselves as cholecystitis (32,56%), gastroduodenitis (48,84%), steatohepatosis, obesity, chronic pancreatitis; entero-colopathies were rare or did not occur at all. According to the history and materials of outpatient documentation they developed long before (7-12 years) the development of OA, their exacerbations were rare and successfully treated with existing therapeutic regimens. However, with the introduction of NSAIDs for joint pain, it was by them that exacerbations of gastroduodenopathies were triggered (drug-induced comorbidity), but in cases when PPI was not used. Cholecystopathies were not a particular problem in the implementation of anti-rheumatic therapy and only occasionally required the use of choleric, anti-inflammatory agents. It should be noted that in its early stages OA manifested itself as the first and less frequently second radiographic stage of oligoarthrosis by Kelhren Lawrence (K-L) grading and a standard anti-rheumatic therapy, including chondroprotector action, was effective.

In the group of patients with OA aged 51-60, one can observe the stratification of I-II degree obesity (67,32%), predominantly abdominal type, and closely related stea-
It is characteristic that OA in patients of this age group acquired a greater systemicity, clinical severity, and radiographically the third stage by K-L prevailed. The patients with OA aged over 60 tended to experience an increased incidence of cholecystitis (59,48%), steatohepatitis (63,79%), manifestations of irritable bowel syndrome (42,24%), with prevalence of diarrhea (18,10%), while the incidence of steatohepatitis, mixed genesis hepatitis and pancreatitis increased slightly (see table 1). However, it is necessary to note their more intense severity and their greater overall duration (5-9 years). The manifestations of these pathological conditions might also be due to an increase in the incidence of obesity (85,34%), especially that of the II degree (66,38%), since all these ailments are caused by significant and perennial alimentary deficiencies of the same type.

In the biochemical aspect, according to the chosen age approach of the research program, there were significant peculiarities as well (tables 2 and 3). As one can see in table 2 patients aged over 50 and especially 60 have progressing disorders in bilirubin metabolism, the activity of ALT, AST, AP, LDG, GGT and glucose rates were increasing moderately but reliably, increasing of uric acid and of creatinine was less significant and the patients aged over 60 experienced a reliable deterioration in calcium-phosphorous exchange and in iron (table 3). Disorders in mineral metabolism were most significant in patients with predominance of enteral events and in those aged over 70, especially in females, to a large extent they correlated with clinical manifestations of cholecysto-hepatic, pancreatic and enterocolopathies. A similar pattern was found regarding lipid metabolism (table 4).

In particular, there was a reliable increase in total cholesterol due to low density lipoproteins and an increase in the anterogeneity rate; the triglyceride rate increased as well. Disorders in lipid metabolism were most common in patients with pronounced manifestations of hepato- and enterocolopathies, as well as with second degree obesity.

Table 1

| nosologic forms | Age group under 50 years n=43 | Age group 51-60 years n=153 | Age group over 60 years n=116 |
|-----------------|-------------------------------|-------------------------------|-------------------------------|
| Gastritis and duodenitis types | 21 (48,84%) | 81 (52,94%) | 61 (54,10%) |
| Ulcer disease | 1 (2,33%) | 6 (3,92%) | 5 (4,31%) |
| cholecystitis types including the calculous ones | 14 (32,56%) | 86 (56,21%) | 69 (59,48%) |
| Steatohepatosis | 1 (2,33%) | 63 (41,18%) | 74 (63,79%) |
| Steatohepatitis | - | 5 (3,27%) | 4 (3,45%) |
| Chronic hepatitis | - | 3 (1,96%) | 2 (1,72%) |
| Chronic pancreatitis | - | 31 (20,26%) | 25 (21,55%) |
| Mixed-Type Irritable Bowel Syndrome including that with diarrhea and constipation | - | 59 (38,56%) | 49 (42,24%) |
| Obesity | 2 (4,66%) | 36 (23,53%) | 22 (18,96%) |
| I degree | 1 (2,33%) | 67 (43,79%) | 77 (66,38%) |
| II degree | 103 (67,32%) | 99 (85,34%) |
| Total | | 103 (67,32%) | 99 (85,34%) |

Note: per cents have been derived from the number of patients in the relevant age groups.

Table 2

| nosologic forms | Age group under 50 years n=43 | Age group 51-60 years n=153 | Age group over 60 years n=116 |
|-----------------|-------------------------------|-------------------------------|-------------------------------|
| Gastritis and duodenitis types | 21 (48,84%) | 81 (52,94%) | 61 (54,10%) |
| Ulcer disease | 1 (2,33%) | 6 (3,92%) | 5 (4,31%) |
| cholecystitis types including the calculous ones | 14 (32,56%) | 86 (56,21%) | 69 (59,48%) |
| Steatohepatosis | 1 (2,33%) | 63 (41,18%) | 74 (63,79%) |
| Steatohepatitis | - | 5 (3,27%) | 4 (3,45%) |
| Chronic hepatitis | - | 3 (1,96%) | 2 (1,72%) |
| Chronic pancreatitis | - | 31 (20,26%) | 25 (21,55%) |
| Mixed-Type Irritable Bowel Syndrome including that with diarrhea and constipation | - | 59 (38,56%) | 49 (42,24%) |
| Obesity | 2 (4,66%) | 36 (23,53%) | 22 (18,96%) |
| I degree | 1 (2,33%) | 67 (43,79%) | 77 (66,38%) |
| II degree | 103 (67,32%) | 99 (85,34%) |
| Total | | 103 (67,32%) | 99 (85,34%) |
Table 2

| Investigated parameters, units. of measurement | Patients with OA aged under 50 (low comorbidity) n=43 | Patients with OA aged 51-60 (Moderate comorbidity) n=153 | Patients with OA aged over 60 (high comorbidity) n=116 |
|-----------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| Glucose, mmol / l                             | 5.6±0.38                                             | 6.1±0.42                                             | 6.8±0.42                                             |
| Total bilirubin, µmol/l                       | 17.2±1.26                                            | 22.8±2.05                                            | 27.3±2.12                                            |
| direct bilirubin, µmol/l                      | 4.64±0.38                                            | 6.32±0.56                                            | 7.34±0.62                                            |
| ALT activity, unit / l                        | 36.4±2.15                                            | 41.6±3.22                                            | 92.2±4.16                                            |
| AST activity, unit / l                        | 39.8±3.16                                            | 84.8±5.36                                            | 105.3±6.22                                           |
| Alkaline phosphatase (AP) activity, unit / l  | 214.2±16.34                                          | 296.4±19.52                                          | 358.5±21.52                                          |
| Total LDG activity, unit / l                  | 346.0±24.36                                          | 482.8±28.14                                          | 516.2±34.54                                          |
| Uric acid, µmol/l                             | 345.3±18.16                                          | 378.4±22.34                                          | 402.3±24.68                                          |
| Creatinine, µmol/l                            | 92.2±4.58                                            | 105.8±8.34                                           | 114.4±11.22                                          |

Note: * - reliability of variation in rates as compared to those in the group of patients with OA aged under 50 (p<0.05-0.001).

Mineral metabolism rates in patients with osteoarthritis due to age level of comorbidity (M±m; p)

Table 3

| Investigated parameters, units. of measurement | Practically healthy individuals n=30 | Patients with OA aged under 50 (low comorbidity) n=43 | Patients with OA aged 51-60 (moderate comorbidity) n=153 | Patients with OA aged over 60 (high comorbidity) n=116 |
|-----------------------------------------------|-------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| Free Ca, mmol / l                             | 1.31±0.12                           | 1.24±0.11                                           | 1.12±0.09                                           | 0.92±0.06                                            |
| Fe, µmol/l                                    | 19.0±1.16                           | 17.1±1.46                                           | 14.6±1.32                                           | 10.2±0.66                                            |
| P, µmol/l                                     | 1.32±0.18                           | 1.12±0.11                                           | 1.04±0.06                                           | 0.71±0.05                                            |
| Mg, mmol/l                                    | 0.96±0.08                           | 0.91±0.06                                           | 0.89±0.04                                           | 0.82±0.05                                            |

Notes: * - reliability of variation in rates as compared to those in the group of patients with OA aged under 50 (p=0.05-0.001) and practically healthy individuals.

Lipidogram findings in patients with osteoarthritis (OA) depending on age comorbidity (M ± m; p)

Table 4

| Investigated parameters, units. of measurement | Patients with OA aged under 50 n=43 | Patients with OA aged 51-60 n=153 | Patients with OA aged over 60 n=116 |
|-----------------------------------------------|-------------------------------------|----------------------------------|------------------------------------|
| Total cholesterol, mmol/l                     | 5.3±0.26                            | 6.1±0.38                         | 6.6±0.42                           |
| LDL cholesterol, mmol / l                    | 2.82±0.24                           | 3.94±0.26                        | 4.16±0.38                          |
| HDL cholesterol mmol / l                     | 1.26±0.09                           | 1.02±0.06                        | 0.88±0.07                          |
| Triglycerides, mmol / l                       | 2.16±0.18                           | 2.8±0.21                         | 3.36±0.24                          |
| Atherogenicity rate, unit / l                 | 3.2±0.16                            | 4.9±0.38                         | 6.5±0.44                           |

Notes: * - reliability of variation in rates as compared to those in the group of patients with OA aged under 50 (p=0.05-0.001).

Taking into consideration that OA, obesity, fatty liver disease, lesions in the pancreas and intestines as well as dyslipidemia are accompanied by manifestations of systemic low-intensity inflammation, the level of which can be rather informatively determined by the CRP values, we have carried out a comparative characteristic of this parameter in accordance with the selected age-related study program. It has been established that in the age group under 50, the level of CRP is higher (3.9 ± 0.24) than in the PHI (2.8 ± 0.18; p <0.05), and in other age groups its level increased progressively: in patients aged 51-60 years - 7.8 ± 0.56 (p <0.01), over 60 - 8.1 ± 0.48 (p <0.001) and was even reliably higher (p <0.001) than in patients with OA of the age group under 50. However, there were no gender differences in this context.

The revealed biochemical disorders, caused mainly by different comorbid processes, form a common non-specific pathogenetic link, namely, the systemic low-intensity inflammation, which is one of the causes of the progression of both OA and vascular-metabolic organ lesions, including atherosclerotic ones, and which also requires medication correction.

Discussion
The analysis of the chrono aspects of the onset and development of OA and comorbid processes shows their pronounced age and, somewhat gender dependence (more pronounced in females). In early stages (group of patients aged under 50), gastroduodenal- and cholecystopathies are frequent, but only moderate in semiotics and favorable course, are, which, with modern means of gastrointestinal, allow successful implementation of anti-rheumatic therapy.

Problems of diagnosis and comprehensive treatment of OA are progressively increasing in people over 50, especially 60, with stratification and progression of diseases in hepatobiliary system and the pancreas, mainly with the development of enterocolopathies with different types of disorders in intestinal digestion and absorption. These comorbid processes, depending on their severity, generate in the later stages of OA new system pathogenetic dependences: disorders in detoxification function of the liver, dyscholia, insufficiency in the pancreas exocrine function → chronic intestinal dyspepsia → dysbiosis with disturbances in the protective function of the intestinal microflora → endogenous intestinal intoxication, malabsorption if important nutrients, especially calcium, phosphorus, iron → system deteriorating trophic processes, including articular apparatus, osteoporosis, and in obesity - extra overloading on bearing joints. Under these conditions, the tolerance of NSAIDs deteriorates with an increased need for their use, their side effects are more frequent (hepato- and enterotoxic effects are manifested), absorption of chondroprotectors decreases, reducing their effectiveness even to the inappropriateness of their use. Perhaps it was this contingent of patients with OA who served as a reason to experts from the American College of Rheumatologists in 2012 not to recommend chondroprotectors for the treatment of patients with OA [8].

Observing French physicians back in the 19th century noticed that patients with prolonged intestinal lesions were not only older than their age, but had joint problems that they described as "dry intestinal rheumatism."

The study of age characteristics of the development of pathological processes in the digestive system should also be considered in the context of background obesity, which is an important part of the metabolic syndrome, provoking the development of various lesions of the cardiovascular system and having a predictive significance as a "gender killer" [11].

Thus, age diversity and severity of comorbid lesions of the HBS and the pancreas, as well as secondary enterocolopathies generate various and increasingly complex pathogenetic situations that are important to study, analyze and, on this basis, build a personalized approach to improving the complex treatment of patients suffering from OA with such comorbidities.

Conclusions

1. In patients with OA in the initial stages (under the age of 50), there are though frequent but mild forms of cholecystopathies, which have no effect on the implementation and effectiveness of modern antirheumatic drugs.

2. In patients with OA aged over 50, especially 60, lesions of the hepatobiliary system and the pancreas against the background of different stages of obesity progressively increase quantitatively and become increasingly marked which is accompanied by secondary enterocolopathies with disorders in motility, digestive processes, absorption and significant progressive biochemical disorders, including mineral metabolism.

3. With the age progression of lesions of the hepatobiliary system, pancreas and the secondary intestinal changes, the results of anti-rheumatic therapy worsen, especially those of chondroprotectors, the frequency of side effects due to their use increases.

4. The study of chrono aspects of developing comorbid pathology in the hepatobiliary system and the pancreas in patients with osteoarthritis can serve as arguments for improving the existing schemes of antirheumatic therapy, to be one of the important factors in the development of personified approaches to the treatment of such a contingent of patients.

Prospects for further research might be considered in the aspect of approbation of modern polycomponent herbal medicines having a systemic action on the lesions of hepatobiliary system, pancreas and intestines in medical complexes of such patients.
Відомості про авторів:
Волошина Л.О. - к.мед.н., доцент кафедри внутрішньої медицини ВДНЗ України "Буковинський державний медичний університет", м.Чернівці

Свідоцтво об авторах:
Волошина Л.А. - к.мед.н., доцент кафедри внутрішньої медицини ВДНЗ України "Буковинський державний медичний університет", м.Чернівці

Information about authors:
Voloshyna L.O. - PhD, assistant professor of the Department of Internal Medicine Higher State Educational Establishment of Ukraine "Bukovinian State Medical University", Chernivtsi

References.
1. Voloshyna LO, Voloshyn OI, Prysiakhniuk VP. Klaster gastroenterologichnych komorbidnykh zakhvoruvannya на osteoartroz: vikovyy aspekty formuvannya ta osoblyvosti farmakolohichnoi korektsii [rezul'taty tryrichnoho prospektivnoho sposterezhennia] [Cluster of gastroenterological comorbid diseases for osteoarthritis: age aspects of formation and features of pharmacological correction (results of three-year prospective observation)]. Suchasna gastroenterologhiia. 2016; 5:40-8. (in Ukrainian).
2. Kovalenko VM. Komorbidnost' i shliakhy ratsonal'noi farmakoterapii v revmatolohii [Comorbidity and ways of rational pharmacotherapy in rheumatology]. Ukrain's'kyi revmatologichnyi zhurnal. 2015;2:7-15. (in Ukrainian).
3. Stasenko T. Osteoartroz: optymal'nii vybіr dla uspi-noho likuvannya [Osteoarthritis: the best choice for successful treatment] [Internet]. Ukrain's'kyi medychnyi chasopys. 2017 [citovano 2017 Sent 10];11-12:20-1. Dostupno: https://mail.google.com/mail/u/1/#inbox/15ee199e31b96ccb?projector=1
4. Suprun JeV. Komorbidnost' pri osteoartrozhe u pozhilyh pacientov: vybor taktiki lechenja [Comorbidity in osteoarthritis in elderly patients: choice of treatment tactics]. Racional'naja farmakoterapija. 2013;5:47-52. (in Russian).
5. Fadieienko HD, Hridniev Ole, Nesen AO, Chernyshova VA, Hrunchenko MM, Shkapo VL. Komorbidnost' i vysoky kardiovascularniy ryzyk - khlopuki pytannia suchasnoi medytsyny [Comorbidity and high cardiovascular risk are the key issues of modern medicine]. Ukrain's'kyi terapevtychnyi zhurnal. 2013;1:102-7. (in Ukrainian).
6. Fadieienko HD, Nesen AO. Komorbidnost' i integrativnaya rol' terapii vnutrishnikh orhaniv [Comorbidity and integrative role of therapy of internal organs]. Ukrain's'kyi terapevtychnyi zhurnal. 2015;2:7-15. (in Ukrainian).
7. Khimion LV. Klymus' IV. Polimorbidnost' v revmatologii. Suchasna paradyhma vedeniya simeinym likarem [Polypharmacy and Rheumatology. Contemporary paradigm of family doctor]. Zdorov'ya Ukrainy. 2016;2:59-61. (in Ukrainian).
8. Hochberg MC, Altman RD, April KT. Hemidikamentoznaja i lekarstvennaia terapiia osteoartrozhe sostavok kist'y, kolennych i tazobedrennyh sostavok. Rekomendacii Ame-rikanskogo koledzha revmatologii (2012) [Non-medicamentous and medicinal therapy of osteoarthritis of the joints of the hand, knee and hip joints. Recommendations of the American College of Rheumatology (2012)]. Zdorov'ya Ukrainy [Internet]. 2012 [citovano 2017 Sent 10];11-12:20-1. Dostupno: https://mail.google.com/mail/u/1/#inbox/15ee199e31b96cbec60?projector=1
9. Leite AA, Coste AJ, Lima Bde A, Padilha AV, Albuquerque EC, Marques CD. Komorbidities in patients with osteoarthritis: frequency and impact on pain and physical function. Rev Bras Reumatol. 2013;Mar;51(2):118-23.
10. Marengoni A, Angleman S, Fratiglioni L. Prevalence of disability according to multimorbidity and disease clustering: a population-based study. J Comorbidity. 2011;1(1):11-8. doi: 10.1007/s11606-011-2659-y.
11. Sherling DH, Perumareddi P, Hennekens ChH. Metabolic syndrome: clinical and policy implications of the new silent killer [Internet]. J Trombo Cir. 2016 [cited 2017 Sept 10];2(3):1000011. Available from: https://www.omicsonline.org/open-access/metabolic-syndrome-clinical-and-policy-implications-of-the-new-silent-killer-JTCAOA-1000111.pdf
12. Uhlig K, Left B, Kent D, Dy S, Brunnhuber K, Burgers JS, et al. A framework for crafting clinical practice guidelines that are relevant to the care and management of people with multimorbidity. J Gen Med Int. 2014 Apr;29(4):670-9. doi: 10.1007/s11606-013-2659-y.
13. Wallace E, Salisbury Ch, Quthrie B, Lewis C, Fahey T, Smith SM. Managing patients with multimorbidity in primary care. BMJ. 2015 Jan 20;350:h176. doi: 10.1136/bmj.h176.
14. Zhang W, Doherty M, Peat G, Bierma-Zeinstra MA, Arden NK, Bresnihan B, et. al. EULAR evidens-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis. 2010 Mar;69(3):483-9. doi: 10.1136/ard.2009.113100.